Guideline for the Management of Parkinson s Disease Medication Trust Reference B26/2017
|
|
- Lisa Cook
- 5 years ago
- Views:
Transcription
1 Guideline for the Management of Parkinson s Disease Medication Trust Reference B26/ INTRUCTION 1.1 Guideline for the management of Parkinson s Disease Medication in adult patients presenting to UHL with Parkinson s Disease. This guideline applies to all staff within UHL who have responsibility for the management of Parkinson s Disease patients. 1.2 Parkinson s Disease (PD) is a complex, neurological condition which requires appropriate management and monitoring. Low et. Al (2015) demonstrated that PD patients have longer inpatient stays and higher hospital mortality rates than other groups of patients. Rapid recognition and appropriate management of PD specific hospital related problems may be delayed given the common lack of expertise in PD management of doctors, nurses, and allied healthcare professionals. Special considerations are required for patients who are admitted into hospital to ensure that symptom control is maintained during the inpatient period. Furthermore, inpatients with PD are at a higher risk of developing Delirium, Chest Infections (particularly Aspiration Pneumonia), Urinary Tract Infections (UTIs), Postural Hypotension and Falls. 1.3 Incidents involving PD medications are common in UHL. These are related to all stages involved in drug therapy; prescribing, administration and supply. Examples include patients designated Nil By Mouth (NBM) going for over a week without administration of any PD medication; patients receiving the incorrect dosage of their intended regimen throughout inpatient stay and usual regimens being altered due to apparent confusion caused by infections such as UTIs resulting in extended inpatient stay. 1.4 Patients with PD often have complex medication regimens with frequent doses throughout the day. Missed doses and inappropriate prescribing can cause deterioration in symptom control, resulting in acute akinesia (rigidity) and decreased mobility. Abrupt withdrawal of PD medications can be life threatening and can precipitate the onset of Neuroleptic Malignant Syndrome (NMS). Guideline for the Management of Parkinson s Disease Medication Page 1 of 13
2 2. GUIDELINE STANDARDS AND PROCEDURES 2.1 KEY RESPONSIBILITIES ON ADMISSION Healthcare Professional(s) HEALTHCARE PROFESSIONAL(S) DOCTOR OR OTHER PRESCRIBER KEY RESPONSIBILITIES Obtain an accurate drug history including timings, doses and strengths of regular and when required medications. Please also note the preparation of the medication e.g. whether it is dispersible or modified release etc. Prescribe medications promptly as per the patient s regular regimen in order to avoid delay in doses. Please note that the electronic prescribing system, EPMA will automatically put in preset times for dosage regimens. IT IS ESSENTIAL TO AMEND THE TIMINGS AS PER HOW THE PATIENT WAS USUALLY TAKING THE TABLETS Consider whether the patient s PD is well controlled. Treat each patient individually and adjust doses accordingly with input from the PD specialist team (See Section 2.15 Contact Details). o If increased stiffness / slowness INCREASE the dose and observe daily. o If increased confusion / hallucinations, DECREASE the dose and review daily. Consider whether the patient is able to self-administer their own medications whilst they are an inpatient. Please fill in a selfadministration assessment form and refer to the UHL selfadministration policy on insite. Administer medication at times prescribed and do not delay or omit doses. NURSING STAFF PLEASE NOTE ADMINISTRATION TIMES ARE UNLIKELY TO MATCH DRUG ROUNDS Consider use of timers as a reminder for administration. Please contact the PD specialist team for more information. PHARMACIST DOSES SHOULD NEVER BE OMITTED DUE TO UNAVAILABILITY SEE SECTION WHERE TO FIND PD MEDICATIONS. Prioritise medicines reconciliation in patients who have PD. Obtain an accurate drug history including timings, doses and strengths of regular and when required medications. Please also note the preparation of the medication e.g. whether it is dispersible or modified release etc. Check patient s own supply of medicine, ward stock availability and order promptly from pharmacy where necessary. Guideline for the Management of Parkinson s Disease Medication Page 2 of 13
3 2.1.2 Preferential Base Wards for PD Patients Where possible, patients should be transferred to wards which have experienced staff in PD management. At the LRI, these wards are 24 (Neurology), 36 (Geriatrics), 31 (Geriatrics) or 29 (Geriatrics) Where to Find Parkinson s Disease Medications Check whether the patient has brought their own medications to hospital. If not or are in a form which is unsuitable such as a dosette box, inform the ward pharmacist well before the next dose is due so that the drugs can be ordered promptly. In case of emergencies and out of hours, PD medication stock cupboards are available on ward 33, 34 and AMU. THERE SHOULD NEVER BE A SITUATION WHERE A DOSE IS MISSED DUE TO MEDICATION UNAVAILABILITY A DATIX should be completed in cases where doses are omitted so that a full investigation can be carried out. 2.2 DISEASE-DRUG INTERACTIONS Certain drugs are contraindicated in PD due to their action on Dopamine Receptors: DRUG Antipsychotics Antiemetics Anticholinergics EXAMPLES Haloperidol, Chlorpromazine, Promazine, Sulpiride, Risperidone Metoclopramide, Prochlorperazine (Domperidone or Cyclizine are preferred antiemetics for PD patients) Oxybutynin, Tolterodine and Tryciclic Antidepressants are best avoided in patients with PD related dementia as they may worsen cognitive function. 2.3 SWALLOWING DIFFICULTIES AND FEEDING TUBES Refer to Speech and Language Therapy (SALT) and to the PD specialist nurses where appropriate (See Section 2.15). NB. Correct posture can contribute to effective swallow. Parkinson s UK (2013) Review whether the gastrointestinal (GI) route is still available if so, please refer to the table (Section Drug Administration via Nasogastric (NG) tubes or Orally with Poor Swallow. Please note a NG tube may not always be appropriate e.g. if the patient is nearing end of life. If in doubt please contact a PD specialist. Consider prescribing dispersible Madopar 62.5mg when required for loss of symptom control alongside medication changes If the GI route is unavailable or inappropriate convert to Rotigotine patches (see Section 2.4.2). Never crush or split modified release preparations Guideline for the Management of Parkinson s Disease Medication Page 3 of 13
4 2.3.1 Drug Adminstration via NG tube or Orally with poor swallow (NEWT Guidelines 2015) DRUG FORMULATION RECOMMENDATION Dispersible Continue Capsules Capsules Convert to Dispersible (Same dose) Co-Beneldopa (Madopar ) Co-Carelodpa (Sinemet ) M/R tabs (Plain Release) Modified Release Convert to Dispersible (Same total daily dose). Inform PD nurse as may need to alter dose / frequency Continue. disperse in water Convert to standard release Co-Careldopa or Dispersible Madopar (Same total daily dose). Inform PD nurse as may need to alter dose / frequency Continue. disperse in water (Plain Pramipexole Release) Modified Release Convert to Plain Release. Divide total daily dose into regimen (Plain Continue. disperse in water Ropinorole Release) Modified Release Convert to plain release tablets. Divide total daily dose into regimen Rasagiline Continue. can be crushed and mixed in water Selegiline Continue. disperse in water Entacapone Continue. Take care if crushing as this produces red dust which may stain. Entacapone does not fully dissolve in water, so if giving via enteral feeding tube, the tube should be flushed well after administration. Carbergoline Continue. disperse in water Entacapone, Levodopa, Carbidopa (Stalevo ) Amantadine Capsules Continue, tablets will disperse in water. If for swallowing difficulties, consider mixing with honey, jam or orange juice they have a bitter taste. Continue. Capsules can be opened and dissolved in water. Medications which can be temporarily omitted in swallowing difficulties COMT Inhibitors: Entacapone, Tolcapone MAOB Inhibitors: Selegine / Rasagiline Guideline for the Management of Parkinson s Disease Medication Page 4 of 13
5 2.4 DOSAGE CONVERSION Online Dosage Conversions An online dosage conversion calculator developed by a team of PD specialists and pharmacists is available via the following link and is especially useful for patients with complex medication regimens Conversion To Rotigotine Patches Rotigotine patches are associated with side-effects including Postural Hypotension, Aggression, Impulse Control Disorders and other Dopaminergic Adverse Reactions such as Hallucinations, Dyskinesia and Peripheral Oedema. It is therefore important that the patient goes back to their usual oral medications once their swallowing function is restored. Please note that patches should NOT be cut. They are available as 2mg/4mg/6mg/8mg patches (More than one patch can be used to make up the total dose) Levodopa to Rotigotine Patches REGIMEN Madopar or Sinemet 62.5mg BD Madopar or Sinemet 62.5mg Madopar or Sinemet 62.5mg QDS Madopar or Sinemet 125mg Madopar or Sinemet 125mg QDS Madopar or Sinemet 187.5mg Madopar or Sinemet 187.5mg QDS Madopar or Sinemet 250mg Madopar or Sinemet 250mg QDS and above TOTAL DAILY DOSE OF LEVOPA 100mg 150mg 200mg 300mg 400mg 450mg 600mg 600mg >600mg RECOMMENDED DOSE OF ROTIGOTINE PATCH / 24HOURS 2mg 4mg 6mg 8mg 10mg 12mg 14mg 16mg 16mg (Max daily dose) and obtain specialist advice. Modified Release Preparations NB: 100mg Levodopa Modified Release is approximately equivalent to 2mg/24hr Rotigotine. For example, if a patient takes Sinemet 62.5mg BD and Half Sinemet CR 125mg NOCTE, this is equivalent to a Rotigotine patch dose of 4mg/24hours. Guideline for the Management of Parkinson s Disease Medication Page 5 of 13
6 Oral Dopamine Agonists to Rotigotine Patches PRAMIPEXOLE PLAIN RELEASE (SALT) 0.125mg 0.25mg 0.5mg 0.75mg 1mg 1.25mg 1.5mg PRAMIPEXOLE MIFIED RELEASE (SALT) 0.375mg 0.75mg 1.5mg 2.25mg 3.0mg 3.75mg 4.5mg ROPINOROLE STANDARD RELEASE 750micrograms 1mg 2mg 3mg 4mg 6mg 8mg ROPINOROLE MIFIED RELEASE N/A 4mg/day 6mg/day 8mg/day 12mg/day 18mg/day 24mg/day RECOMMENDED DOSE OF ROTIGOTINE PATCH / 24HOURS 2mg 4mg 6mg 8mg 12mg 16mg 16mg Max daily dose) and obtain specialist advice Conversion of Stalevo to Rotigotine Patches REGIMEN Stalevo 50/12.5/200 Stalevo 100/25/200 Stalevo 100/25/200 QDS Stalevo 150/37.5/200 Stalevo 200/50/200 RECOMMENDED DOSE OF ROTIGOTINE PATCH / 24HOURS 6mg 10mg 14mg 16mg 16mg Guideline for the Management of Parkinson s Disease Medication Page 6 of 13
7 2.5 APOMORPHINE Apomorphine is a Non-Ergot Dopamine Agonist which is delivered as an intermittent Subcutaneous Injection or a Pump. It must NOT be used via the Intravenous route On Admission Patients who are already on an established Apomorphine routine need to be continued at the prescribed dose and frequency of subcutaneous injection or rate of pump. Assess whether the patient administers Apomorphine themselves and whether they are capable of continuing this during their hospital stay Assess whether a relative or carer usually administers the Apomorphine and whether they are willing to continue to do so during the patient s hospital stay Determine whether the patient has brought in all the relevant Apomorphine equipment and medication with them with them e.g. APO-go pump, prefilled syringes, chrono syringes or connectors If patients are on the pump device determine their usual flow rate. A treatment free period is usually observed during sleeping hours, unless the patient has severe night time symptoms. Check the patients understanding and refer to recent neurology appointment letters Equipment Unavailable Check whether the patient has brought their own equipment in. If not, consider contacting the APO-go nurse advisor (See Section 2.15). Equipment can also be ordered from pharmacy via your Ward Pharmacist. For out of hours supply please contact the on-call pharmacist via switch board Initiation Apomorphine should be initiated by a specialist only. Patients treated with Apomorphine will usually need to start Domperidone at least two days prior to initiation of therapy. The Domperidone dose should be titrated to the lowest effective dose and discontinued as soon as possible. Before the decision to initiate Domperidone and Apomorphine treatment, risk factors for QT interval prolongation in the individual patient should be carefully assessed to ensure that the benefit outweighs the risk 1mg of Apomorphine HCl (0.1ml), may be injected subcutaneously during a hypokinetic or 'OFF' period and the patient is observed over 30 minutes for a motor response. If no response or an inadequate response is obtained, a second dose of 2 mg of Apomorphine HCl (0.2ml) is injected subcutaneously. Thereafter, increase dose at minimum of 40 minute intervals until a satisfactory result is obtained. The daily dose of Apomorphine as a subcutaneous injection varies widely between patients, typically within the range of 3mg-30mg, given as 1-10 injections and sometimes as many as 12 separate injections per day Patients who have shown a good 'ON' period response during the initiation stage of Apomorphine therapy, but whose overall control remains unsatisfactory using intermittent injections, or who require many and frequent injections (more than 10 Injections per day), may be commenced on or transferred to a continuous subcutaneous infusion by minipump and/or syringe driver. Intermittent bolus boosts are also usually needed on top of this. Please refer to the PD specialist team if initiation is required. Guideline for the Management of Parkinson s Disease Medication Page 7 of 13
8 2.6 SURGERY Ensure morning doses of PD medications are prescribed and given prior to the surgical procedure even if the patient is Nil By Mouth (NBM). Clearly mark the drug chart (Paper or EPMA) that they must be given prior to surgery. Prioritise patients with PD to the top of the surgery list If the patient s medication regimen will be interrupted by surgery or if the total duration of surgery is over 6 hours, please contact the specialist PD nurse for advice on adjustment to therapy. If the patient has had Deep Brain Stimulation (DBS), please ensure that the surgeon is aware prior to the surgical procedure. Anti-dopaminergic anti-emetics such as Metoclopramide should be avoided (see under Disease Drug Interactions) 2.7 ORTHOSTATIC HYPOTENSION Moderate orthostatic hypotension occurs in at least 20% of patients and may be related to the disease itself or PD medications. Non-pharmacological treatment includes increasing sodium intake, use of compression stockings, improved hydration, and raising the head of the bed on blocks. Review non-pd medications to see whether they can be stopped or the dose can be reduced, for example Diuretics, Antidepressants, Proton Pump Inhibitors, Anti-hypertensives, Antipsychotics and Anticholinergics. Please note that certain medications such as Antipsychotics should not be stopped suddenly please contact your Ward Pharmacist for advice. Consider asking the PD specialist team to review the PD medication to see whether Dopaminergic medication can be reduced. Consider a trial with Midodrine, taking into account contraindications and monitoring requirements. This can be switched to Fludrocortisone if Midodrine is contraindicated / not tolerated or ineffective. Do not continue pharmacological treatment if no benefit is observed 2.8 DEPRESSION Depression occurs in approximately 80% of all PD patients and can significantly affect quality of life. Depression may be under diagnosed in PD because the clinical features of depression overlap with motor features of PD (NICE 2006) Although non-pharmacological treatment such as counselling may be helpful, the mainstay treatment is medication as the pathological cause is thought to be organic in PD (Lyons 2011). Management of depression should be tailored to the individual, in particular, to their co-existing therapy. First line therapy is usually a Selective Serotonin Reuptake Inhibitor (SSRI) or Mirtazapine. 2.9 SLEEP DISTURBANCE Up to 98% of PD patients experience sleep disturbance which may be exacerbated during a patients inpatient stay. All patients should try to maintain good sleep hygiene and be counselled on the importance of keeping up a regular sleep schedule. Disturbed sleep could be a manifestation of OFF symptoms during the night and therefore evening Modified Release preparations can be considered with specialist input. Dopamine Agonists can cause insomnia and therefore these medications may require dose or timing adjustments. Clonazepam 250micrograms at night can be trialled for pharmacological management of insomnia in PD patients. Please review duration and efficacy regularly and consider stopping prior to discharge if appropriate. Guideline for the Management of Parkinson s Disease Medication Page 8 of 13
9 2.10 MANAGEMENT OF DELIRIUM OR PSYCHOSIS Refer to the UHL Trust Guidelines on Delirium for general management principals. Wherever possible, seek to reassure the patient using a calm manner. If the patient finds the presence of family comforting and reassuring, please contact them to come in, even if outside of conventional visiting hours. Look for underlying causes of Delirium or Psychosis such as Dehydration, Chest Sepsis, Hypoxia, Electrolyte Disturbance, Urinary Tract Infections and Constipation. Review the patient s non-pd medications first to see whether these are contributing to the patient s acute confusional state. For example, Anticholinergics such as Solifenacin, Tricyclic Antidepressants and Opiates can affect cognition. Consideration should be given to withdrawing or reducing PD medication that might have triggered Delirium or Psychosis (NICE 2017). Specialist input would be necessary from the PD team. Pharmacological interventions should be avoided wherever possible. If the patient is very agitated or aggressive consider using Quetiapine PO 12.5mg 25mg Daily to Twice Daily or Lorazepam 0.5mg-1mg (PO or IM) (Risk of Falls and Respiratory Depression with IM) Typical Antipsychotic drugs such as Haloperidol and Chlorpromazine should be avoided MANAGEMENT OF CONSTIPATION Encourage adequate fluid intake and mobilisation where appropriate. Review diet including fibre intake First line pharmacological treatment is an Osmotic Laxative such as Macrogol 1-2 sachets twice a day in combination with a stimulant laxative such as Senna 7.5mg 15mg at night DISCHARGE CONSIDERATIONS Clearly document any inpatient PD reviews or medication changes on the discharge letter A copy of the discharge letter should be sent to the patient s PD consultant as soon as possible ADVANCED CARE PLANNING Please refer to any advanced care planning that has taken place to ease decision making. This may be in the form of an Advanced Decision to Refuse Treatment, a Do Not Attempt Resuscitation (DNACPR) or the appointment of a Lasting Power of Attorney for Finance and/or health and social care END OF LIFE MEDICATIONS PD medications are critical, however are sometimes stopped in the last stage of life after clinical review. Please consider contacting a PD specialist for further input For symptom control, when required Midazolam can help with rigidity as well as agitiation. Levomepromazine should be avoided. Instead, consider use of Cyclizine for management of nausea and vomiting Guideline for the Management of Parkinson s Disease Medication Page 9 of 13
10 2.15 CONTACT Parkinson s Disease Specialist Nurses Elizabeth Hillman Mobile: Tel: Elizabeth.Hillman@uhl-tr.nhs.uk Kesha Obi Tel: Kesha.obi@uhl-tr.nhs.uk Neurology Outpatients Leicester General Hospital Consultant Neurologists Dr.Peter Critchley Tel Peter.Critchley@uhl-tr.nhs.uk Brain Injury Unit Leicester General Hospital Durban Simpson Tel: Mobile: Ben.Simpson@uhl-tr.nhs.uk Consultant in Acute Medicine Dr. Juan Cardenas Tel: Mobile: Juan.Cardenas@uhl-tr.nhs.uk Consultant Geriatricians Dr Victoria Haunton Tel: Mobile: Victoria.Haunton@uhl-tr.nhs.uk Dr. Glen Harper Tel: Glen.harper@uhl-tr.nhs.uk Dr. James Reid Tel: Mobile: james.reid@uhl-tr.nhs.uk Pharmacists David Kearney Lead CMG Pharmacist for Medicine Mobile: David.kearney@uhl-tr.nhs.uk Reena Raithatha Lead Pharmacist for Geriatrics Mobile: Reena.raithatha@uhl-tr.nhs.uk Guideline for the Management of Parkinson s Disease Medication Page 10 of 13
11 Anna Delf Lead Pharmacist for Geriatrics Mobile: Ward Pharmacist Cluster phone number specific to your ward Main Pharmacy: On-call pharmacist available 24 hours via switchboard Nurse Advisor in Apo-go Therapy Liz Carter Tel: Mobile: Education and Training No additional education or training is required 4. Monitoring Compliance What will be measured to monitor compliance Number of Parkinson s Disease medication doses omitted or delayed How will compliance be monitored Audit Monitoring Lead Dr Victoria Haunton Frequency Quarterly Reporting arrangements 5. Supporting References (maximum of 3) 1 Fife Guidelines (2013).Acute management of Parkinson s Version No. 2. Approved on behalf of NHS Fife by the Fife Area Drugs & Therapeutics Committee 2 National Institute for Health and Care Excellence (NICE) Parkinson s Disease in over 20s: diagnosis and management. CG35 June NEWT Gudielines, Administration of medication to patients with enteral feeding tubes or swallowing difficulties (2015) Copyright 2015 J Smyth, BetsiCadwaladr University Local Health Board (East). Available at 6. Key Words Parkinsons Disease, Co-Careldopa, Rotigotine, Apomorphine, Levodopa, Madopar, Sinemet CONTACT AND REVIEW DETAILS Guideline Lead (Name and Title) Executive Lead Dr Victoria Haunton (Geriatrician) Medical Director Contributing Authors Anna Delf (Lead Pharmacist for Geriatrics) Reena Raithatha (Lead Pharmacist for Geriatrics) Details of Changes made during review: July/August 2018 modified release statement and correction of Sinemet spelling Guideline for the Management of Parkinson s Disease Medication Page 11 of 13
12 7. Appendices APPENDIX 1 PARKINSON S DISEASE - QUICK REFERENCE GUIDE For more details, please refer to the full Parkinson s Disease (PD) Policy available on Insite Key Contact Details Parkinson s Disease Specialist Nurses Consultant Geriatrician Consultant Neurologist Elizabeth Hillman / Kesha Obi Elizabeth.Hillman@uhl-tr.nhs.uk Kesha.Obi@uhl-tr.nhs.uk Dr Victoria Haunton Victoria.Haunton@uhl-tr.nhs.uk Dr Ben Simpson Ben.Simpson@uhl-tr.nhs.uk Main Priorities Obtain an accurate drug history including timings, doses, formulations and strengths of all regular medications. Prescribe medications as per the patient s regular regimen. If the patient has not brought in sufficient medication, inform the ward pharmacist well before next dose is due so that the drugs can be ordered promptly. Administer at times prescribed (these are unlikely to correlate with routine drug rounds) Do not prescribe centrally acting dopamine antagonists e.g. antipsychotics such as Haloperidol, Metoclopramide etc. PD medications are CRITICAL and should NOT be omitted. Missed doses cause deterioration in symptom control and can be life threatening. Preferential Base Wards for PD Patients Ideally, patients should be transferred to wards which have experienced staff in PD management. At the LRI, these wards are 24 (neuro), 36 (geriatrics), 31 (geriatrics) or 29 (geriatrics). Where to Find PD Medications out of hours In case of emergencies and out of hours, PD medication stock cupboards are available on ward 33, 34 and AMU. If necessary, contact on-call pharmacist via switch Guideline for the Management of Parkinson s Disease Medication Page 12 of 13
13 Swallowing Difficulties and Feeding tubes Is the gastrointestinal (GI) route still available? NO Convert to Rotigotine patches. Please use online calculator or refer to full reference guide YES Can the patient swallow liquids? YES Refer to table opposite NO Consider urgent NG insertion and refer to table opposite. If the patient is likely to miss doses before the NG tube is place, please consider temporary switch to Rotigotine patches. DRUG FORMULATION RECOMMENDATION Dispersible Continue Co-Beneldopa Capsules (Madopar ) Capsules Convert to Dispersible (Same dose) Co-Carelodpa (Sinemet ) Pramipexole Ropinorole M/R M/R (Plain Release) M/R (Plain Release) M/R Convert to Dispersible (Same total daily dose). Inform PD nurse as may need to alter dose / frequency Continue. disperse in water Convert to standard release Co-Careldopa or Dispersible Madopar (Same total daily dose). Inform PD nurse as may need to alter dose / frequency Continue. disperse in water Convert to plain release tablets. Divide total daily dose into regimen Continue. disperse in water Convert to plain release tablets. Divide total daily dose into regimen Rasagiline Continue. disperse in water Selegiline Continue. disperse in water Entacapone Continue. Take care if crushing as this produces red dust which may stain. Entacapone does not fully dissolve in water, so if giving via enteral feeding tube, the tube should be flushed well after administration. Entacapone, Levodopa, Carbidopa (Stalevo ) Continue, tablets will disperse in water. If for swallowing difficulties, consider mixing with honey, jam or orange juice they have a bitter taste. Guideline for the Management of Parkinson s Disease Medication Page 13 of 13
Clinical Guideline for the management of inpatients with Parkinson s disease
Clinical Guideline for the management of inpatients with Parkinson s disease Introduction: Parkinson s disease (PD) is the second most common neurodegenerative disorder, characterised by bradykinesia,
More informationAcute management of in-patient Parkinson s Disease patients
Acute management of in-patient Parkinson s Disease patients Contents Pages Introduction and Admission advice 2 Nil by Mouth Guidance 3 5 Complex therapy advice (Apomorphine, DBS, Duodopa) 6 Surgical peri-operative
More informationMANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW
MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW Author: Gordon W Duncan Status: Approved Authorised by: Clinical Policy Group Version: 1.0 Review date:
More informationAppendix 2: Admissions checklists for people with Parkinson s
Appendix 2: Admissions checklists for people with Parkinson s This document is intended to form the basis of a locally developed tool and so it has been built to be amended with relevant local information,
More informationACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM
ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD
More informationGuidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth
Index No: MMG48 Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth Version: 2.0 Date ratified: November 2017 Ratified by: (Name of Committee) Name
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationCLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE
CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE 1. Aim/Purpose of this Guideline To assist all doctors and nurses in the care of inpatients with Parkinson s disease. This guideline
More informationMedicines Management and the Unwell Parkinson s Patient
Medicines Management and the Unwell Parkinson s Patient Belinda Kessel Geriatrician and Movement Disorder Specialist Princess Royal University Hospital Orpington, Kent The Society for Acute Medicine, 7
More informationEffective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )
Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationParkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust
n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust The symptoms of Parkinson s appear when the levels
More informationManagement of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth.
Management of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth. To aid the management and treatment of Parkinson s Patients
More informationCommonly encountered medications and their side effects - what the generalist needs to know
Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationShared Care Agreement Apomorphine For use in Parkinson s Disease
Shared Care Agreement Apomorphine For use in Parkinson s Disease This shared care agreement outlines suggested ways in which the prescribing responsibilities can be shared between the specialist and GP.
More informationGUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE (PD) ADMITTED TO HOSPITAL. Reviewer s Name, Title & address:
GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE (PD) ADMITTED TO HOSPITAL Record Type Clinical Guideline elibrary ID Reference No: CG 1813 Newly developed and approved Trust-wide Clinical
More informationRenal Palliative Care Last Days of Life
Renal Palliative Care Last Days of Life Introduction This guideline is an aid to clinical decision-making and good practice for patients with stage 4-5 chronic kidney disease (egfr
More informationDorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE
SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE INDICATION By inhibiting metabolism of levodopa, entacapone or opicapone allow a reduction
More informationAPOMORPHINE (Adults) Shared Care Guidelines DRUG:
Shared Care Guidelines DRUG: APOMORPHINE (Adults) Indication: Treatment of motor fluctuations in patients with Parkinson's disease which is not sufficiently controlled by oral anti-parkinson medication.
More informationCare in the Last Days of Life
Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient
More informationParkinson's Disease and how you can make a difference with medication
Parkinson's Disease and how you can make a difference with medication Alyson Franks Parkinson's and Movement Disorder Nurse Specialist Royal Hallamshire Hospital No treatment all Complementary Therapy
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationLet s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016
Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016 What is Parkinson s? Parkinson's is a progressive neurological condition. People
More informationDelirium. Quick reference guide. Issue date: July Diagnosis, prevention and management
Issue date: July 2010 Delirium Diagnosis, prevention and management Developed by the National Clinical Guideline Centre for Acute and Chronic Conditions About this booklet This is a quick reference guide
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationPAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE
PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE Reference: DCM029 Version: 1.1 This version issued: 07/06/18 Result of last review: Minor changes Date approved by owner (if applicable): N/A
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationBest Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
More informationSupporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety
Agitation & Anxiety (Exclude or treat REVERSIBLE causes*) Patient is anxious / frightened, but lucid Patient is confused, agitated and / or hallucinating MIDAZOLAM 2.5-5mg s/c (Max total 24 hour dose of
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex
More informationPRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT
PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT A collaboration between: St. Rocco s Hospice, Bridgewater Community Healthcare NHS Trust, NHS Warrington Clinical Commissioning Group,
More informationMid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care
Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage
More informationIntervention Study 2016 West ISD. Gillian Ritchie Clinical Pharmacist
Intervention Study 2016 West ISD Gillian Ritchie Clinical Pharmacist Introduction Annual data collection Two weeks All Medicines Management Team interventions Details recorded Classified by type Outcomes
More informationCONTROLLED DOCUMENT. Guidelines for the use of subcutaneous hydration in palliative care (hypodermoclysis) Controlled Document Number: CG259
Guidelines for the use of subcutaneous hydration in palliative care (hypodermoclysis) CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: Controlled Document Number: Version Number: 1 Controlled Document Sponsor:
More informationAn Overview of Parkinson s Medication used in Multiple System Atrophy
Introduction The cause of Parkinson s symptoms The types of Parkinson s drugs used in MSA Finding the best medication Additional medication Drugs to avoid Further information An Overview of Parkinson s
More informationAlgorithms for Symptom Management. In End of Life Care
Algorithms for Symptom Management In End of Life Care The Use of Drugs Beyond Licence (off label) -The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK regulates the activity of the
More informationAn Overview of Parkinson s Medication used in Multiple System Atrophy
Introduction Cause of Parkinson s symptoms Parkinson s drug use in MSA Finding the best medication Other medication - Interaction Drugs to avoid Further information An Overview of Parkinson s Medication
More informationParkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationBJF Acute Pain Team Formulary Group
Title Analgesia Guidelines for Acute Pain Management (Adults) in BGH Document Type Issue no Clinical guideline Clinical Governance Support Team Use Issue date April 2013 Review date April 2015 Distribution
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationEmergency Control of the Acutely Disturbed Adult Patient GUIDELINES ON EMERGENCY CONTROL OF THE ACUTELY DISTURBED ADULT PATIENT... 2 ACTION...
Delirium Toolkit Emergency Control of the Acutely Disturbed Adult Patient Table of Contents GUIDELINES ON EMERGENCY CONTROL OF THE ACUTELY DISTURBED ADULT PATIENT... 2 ACTION... 2 AFTERCARE... 3 NOTES...
More informationTRANSPARENCY COMMITTEE OPINION. 18 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379
More informationPalliative care for heart failure patients. Susan Addie
Palliative care for heart failure patients Susan Addie Treatments The most common limiting and distressing complaint is of fatigue and breathlessness. Optimal treatment strategies relieve symptoms, improves
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More informationFor patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.
Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative
More informationAppendix N: Research recommendations
Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist
More informationFormulary and Clinical Guideline Document Pharmacy Department Medicines Management Services
Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services VIOLENCE, AGGRESSION OR SEVERE BEHAVIOURAL DISTURBANCE Introduction During an acute episode or illness, some
More informationFull details and resource documents available:
Clinical & Regulatory News by Pharmerica Urinary Tract Infection (UTI) Second Most Common Cause of Hospital Readmission within 30 days UTIs are prevalent and account for up to 22% of infections in LTC,
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationUnderstanding your take home medications from the surgical ward. Information for Patients
Understanding your take home medications from the surgical ward Information for Patients i Information for Patients Please read this leaflet before taking the medications that have been prescribed for
More informationEnd of life prescribing guidance
End of life prescribing guidance Introduction This guidance has been prepared to ASSIST IN DECISION MAKING for the prescribing and monitoring of medicines useful in the management of symptoms commonly
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationPAIN MANAGEMENT Patient established on oral morphine or opioid naive.
PAIN MANAGEMENT Patient established on oral morphine or opioid naive. Important; It is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationAcute painful crisis in patients with sickle cell disease: Clinical Guidelines (HN-506a)
Acute painful crisis in patients with sickle cell disease: Clinical Guidelines (HN-506a) Introduction The majority of acute painful crises in patients with sickle cell disease will be managed independently
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationMMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life
MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life The following pages are guidelines for the management of common symptoms for a person thought to be
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationCritical Care Pharmacological Management of Delirium
Critical Care Pharmacological Management of Delirium Policy Title: in the Critical Care Unit Executive Summary: This policy provides guidance Pharmacological Management of delirium in the Critical Care
More informationGUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117
More informationS H A R E D C A R E G U I D E L I N E Drug: Apomorphine Indication Parkinson s Disease
S H A R E D C A R E G U I D E L I N E Drug: Apomorphine Indication Parkinson s Disease Introduction Indication: Treatment of Parkinson s Disease with Apomorphine Background: Patients with Parkinson s disease
More informationB Kessel - BGS Aut 2009
www.bgsmds.org.uk www.bgsmdslive.org/ Fifth British Geriatrics Society Movement Disorders Section Award medical, nursing and therapy students are invited to submit an essay title can we change outcomes
More informationPSYCHOTROPIC SOLUTIONS
PSYCHOTROPIC SOLUTIONS A proactive approach to antipsychotic medication management A Quality Use of Medicines initiative by Choice Aged Care Copyright 2018 Hello everyone. Today we will be discussing the
More informationPAIN MANAGEMENT Person established taking oral morphine or opioid naive.
PAIN MANAGEMENT Person established taking oral morphine or opioid naive. Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationInitiation of Clozapine Treatment Community Patients
Initiation of Clozapine Treatment Community Patients Who Should Read This Policy Target Audience All clinical staff working in the community N/A N/A Initiation of Clozapine Treatment for Patients in the
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationParkinson s disease. Quick reference guide. Issue date: June Diagnosis and management in primary and secondary care
Quick reference guide Issue date: June 2006 Parkinson s disease Diagnosis and management in primary and secondary care Developed by the National Collaborating Centre for Chronic Conditions Contents Contents
More informationPARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information
OHSU PARKINS ON CENTER Parkinson s Disease: Diagnosis and Management for Every MD Disclosure Information Grants/Research Support: National Parkinson Foundation, NIH, Michael J. Fox Foundation Consultant:
More informationHOW TO MANAGE MY SYMPTOMS & MEDICINES PARKINSON S PASSPORT. On time, every time with Parkinson s medicines. Endorsed by Australian College of Nursing
HOW TO MANAGE MY SYMPTOMS & MEDICINES PARKINSON S PASSPORT On time, every time with Parkinson s medicines Endorsed by Australian College of Nursing How to use your Parkinson s Passport Use the Parkinson
More informationCare of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.
Care of the Dying Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance covers the prescribing and management of patients
More informationXADAGO (safinamide) oral tablet
XADAGO (safinamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationALCOHOL WITHDRAWAL GUIDELINES
ALCOHOL WITHDRAWAL GUIDELINES Policy author Accountable Executive Lead Approving body Policy reference Dr M Lewis, Gastroenterologist; Professor J A Vale, Clinical Toxicologist; Dr D A Robertson, Alcohol
More informationParkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More informationESSENTIAL CARE AFTER AN IN-PATIENT FALL
ESSENTIAL CARE AFTER AN IN-PATIENT FALL In line with the National Patient Safety Agency Rapid Response Report (NPSA/2011/RRR001): Essential care after an inpatient fall, in caring for a patient who has
More informationConservative Management of Uraemia
Conservative Management of Uraemia Information for Health Professionals Renal Department The York Hospital and Scarborough Hospital Tel: 01904 725370 For more information, please contact: The Renal Specialist
More informationNorth Wales Critical Care Network
North Wales Critical Care Network SEDATION GUIDELINES FOR ADULTS IN CRITICAL CARE Approved 6.9.12 1 Sedation guidelines for intensive care Betsi Cadwaladr University Health Board (Adapted from guidelines
More informationCare of the Dying Management in Severe Renal Failure
Care of the Dying Management in Severe Renal Failure Clinical Guideline Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance
More informationSHARED CARE PRESCRIBING GUIDELINE. TOLCAPONE for the Treatment of IDIOPATHIC PARKISON S DISEASE.
WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG and Crawley, Horsham & Mid-Sussex
More informationPSYCHOTROPIC SOLUTIONS
PSYCHOTROPIC SOLUTIONS A proactive approach to antipsychotic medication management A Quality Use of Medicines initiative by Choice Aged Care Copyright 2018 Key Senate Committee Recommendations: All RACF
More informationDrug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:
More informationCardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.
Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor
More informationSIFROL â. Contraindications Hypersensitivity to pramipexole or any other component of the product.
SIFROL â Composition 1 tablet contains 0.088, 0.18 & 0.7 mg (S) 2 amino 4,5,6,7-tetrahydro-6-propylamino-benzothiazole (= pramipexole base) equivalent to 0.125, 0.25 & 1 mg of pramipexole dihydrochloride
More informationSummary of Patient < 3y at Visit 11 (90 months)
Summary of Patient < 3y at 11 (90 months) Clinician Scoring Page Direct online data entry available? Medication 378 Yes BPW 382 Yes Diagnostic Features 383 Yes UPDRS Clinician 388 Yes CISI-PD 397 Yes MoCA
More informationPrimary Care Constipation Guidelines. Version 1 November 2016
Primary Care Constipation Guidelines Version 1 November 2016 VERSION CONTROL Version Date Amendments made Version 1 November 2016 New guideline Contents 1. Management of constipation in adults: acute and
More informationSymptom Management Guidelines for End of Life Care
Symptom Management Guidelines for End of Life Care The following pages are guidelines for the management of common symptoms in the last few days of life. General principles: 1. Consider how symptoms can
More informationSupportive Care. End of Life Phase
Supportive Care End of Life Phase Guidelines for Health Care Professionals In the care of patients with established renal failure who are in the last days of life References: Chambers E J (2004) End of
More informationPD: Key Treatment Considerations
PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment
More informationManaging Hyperglycaemia in Acute (Adult) Inpatients Requiring Enteral Feeding Guidelines
Document Control Title Managing Hyperglycaemia in Acute (Adult) Inpatients Requiring Author Author s job title Specialist Nurse Consultant Physician Department Directorate Unscheduled Care Version Date
More informationAny interventions, where RCTs in PD are not available, are not included in the tables.
Tables Interventions where new studies have been published are indicated in bold italics. Changes in conclusions are indicated in italics and are highlighted in yellow. Any interventions, where RCTs in
More informationShared Care Guideline
Shared Care Guideline Rotigotine Executive Summary Indication: Parkinson s disease, either alone or as an adjunct to co-beneldopa or co-careldopa. Patient Group: Patients with early-stage idiopathic Parkinson
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationParkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care
Parkinson's Disease Prescribing Guidelines for use in Primary and Secondary Care 2017 Parkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care Document Description Document Type
More informationDrugs used in Parkinsonism
Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More information